CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations

[1]  I. Vaz-Luis,et al.  F1000Prime recommendation of Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. , 2013 .

[2]  H. Brauch,et al.  Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Greil,et al.  CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8 , 2012, Clinical Cancer Research.

[4]  Yusuke Nakamura,et al.  Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. , 2012, Journal of the National Cancer Institute.

[5]  V. Stanton.  Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. , 2012, Journal of the National Cancer Institute.

[6]  J. Cuzick,et al.  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. , 2012, Journal of the National Cancer Institute.

[7]  P. Neven,et al.  CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. , 2012, Journal of the National Cancer Institute.

[8]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[9]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[10]  J. Ibrahim,et al.  Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Fehm,et al.  Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma , 2011, Clinical pharmacology and therapeutics.

[12]  Jeffrey L. Anderson,et al.  Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial , 2010, Trials.

[13]  P. Fasching,et al.  CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification , 2010, Clinical Cancer Research.

[14]  A. Howell,et al.  Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy , 2010, Breast Cancer Research and Treatment.

[15]  D. Berry,et al.  Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium. , 2009 .

[16]  M. Beckmann,et al.  Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.

[17]  Norah Lynn Henry,et al.  Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients , 2009, The Pharmacogenomics Journal.

[18]  C I Li,et al.  Differential patterns of allelic loss in estrogen receptor‐positive infiltrating lobular and ductal breast cancer , 2008, Genes, chromosomes & cancer.

[19]  M. Schwab,et al.  Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation , 2008, Analytical and bioanalytical chemistry.

[20]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Fergus J Couch,et al.  Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[23]  Zeruesenay Desta,et al.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. , 2003, Journal of the National Cancer Institute.

[24]  V. Jordan,et al.  Tamoxifen: a most unlikely pioneering medicine , 2003, Nature Reviews Drug Discovery.

[25]  Y. Nakamura,et al.  Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  J. Gusella,et al.  A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. , 2000, Cancer research.

[27]  T. Hidaka,et al.  Effects of vitamin E, vitamin B2 and selenite on DNA single strand breaks induced by sodium chromate (VI). , 1987, Cancer letters.

[28]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.